



## Clinical trial results:

**A prospective, multi-center, Phase 1b/2a study to assess the safety and tolerability of different doses of AG019 administered alone or in association with teplizumab in patients with clinical recent-onset Type 1 Diabetes Mellitus (T1D)**

### Summary

EudraCT number	2017-002871-24
Trial protocol	BE
Global end of trial date	13 October 2021

### Results information

Result version number	v2 (current)
This version publication date	09 July 2022
First version publication date	03 June 2022
Version creation reason	• Changes to summary attachments wrong version of CSR synopsis was uploaded by accident, it is therefore replaced by the correct synopsis.
Summary attachment (see zip file)	Figure and tables synopsis (Figure and tables for EudraCT.pdf) CSR Synopsis (CSR Synopsis EudraCT.pdf)

### Trial information

#### Trial identification

Sponsor protocol code	AG019-T1D-101
-----------------------	---------------

#### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03751007
WHO universal trial number (UTN)	-

Notes:

#### Sponsors

Sponsor organisation name	Precigen ActoBio T1D, LLC
Sponsor organisation address	20374 Seneca Meadows Parkway, Germantown, MD 20876, United States,
Public contact	Sven Blomme, Precigen ActoBio, abt.info@actobio.com
Scientific contact	Sven Blomme, Precigen ActoBio, abt.info@actobio.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	15 November 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	13 October 2021
Global end of trial reached?	Yes
Global end of trial date	13 October 2021
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To assess the safety and tolerability of different doses of AG019 alone as well as in association with teplizumab.

Protection of trial subjects:

Trial participants were protected by implementing safety measures for recruitment (staggered recruitment, data review by medical monitor before enrolling the next staggered patient), DSMB data review before opening the next cohort for recruitment, and close follow-up by site, medical monitor and DSMB (including scheduled data reviews).

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	20 October 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 12
Country: Number of subjects enrolled	United States: 33
Worldwide total number of subjects	45
EEA total number of subjects	12

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	19

Adults (18-64 years)	26
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

AG019 monotherapy cohorts: a total of 8 single dose patients and 19 repeat dose patients

AG019/teplizumab combination cohorts: a total of 18 patients

### Pre-assignment

Screening details:

Key eligibility criteria (to assess within 28d of treatment start):

- 18-40y, or 12-17y
- diagnosis of diabetes according to ADA criteria
- positive for at least 1 T1D autoantibody
- treatment to be started within 150 days of diagnosis
- at least 0.2 nmol/L of C-peptide following mixed meal tolerance test
- No active infections

### Period 1

Period 1 title	overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor, Data analyst, Carer, Assessor

Blinding implementation details:

The trial consisted of 2 phases.

Phase 1b was open label. 4 AG019 monotherapy cohorts were sequentially opened (ascending dose groups and descending age groups). Each cohort enrolled 2 single dose patients and up to 6 repeat dose patients.

Phase 2a was double blind (randomization ratio 4:1). 2 AG019/teplizumab combination cohorts were sequentially opened (descending age groups). In each cohort, 2 open label patients were enrolled prior to opening the double blind portion.

### Arms

Are arms mutually exclusive?	No
<b>Arm title</b>	PHASE 1B - Single Low Dose - Adult

Arm description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat Low Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Arm type	Experimental
Investigational medicinal product name	AG019 Single Low Dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

Dosage and administration details:

In this arm, AG019 was administered as a single low dose (one-day dosing; one capsule in the morning and one capsule in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

<b>Arm title</b>	PHASE 1B - Single High Dose - Adult
------------------	-------------------------------------

**Arm description:**

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability.

After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat High Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Arm type	Experimental
Investigational medicinal product name	AG019 Single High Dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

In this arm, AG019 was administered as a single high dose (one-day dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

<b>Arm title</b>	PHASE 1B - Repeat Low Dose - Adult
------------------	------------------------------------

**Arm description:**

In this arm, 4 newly identified repeat low dose adult (18-42y) patients were enrolled. In addition, one of the 2 single low dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.

All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Arm type	Experimental
Investigational medicinal product name	AG019 Repeat Low Dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

In this arm, AG019 was administered as a repeated low dose (8-week dosing; one capsule in the morning and one capsule in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

<b>Arm title</b>	PHASE 1B - Repeat High Dose - Adult
------------------	-------------------------------------

**Arm description:**

In this arm, 4 newly identified repeat high dose adult (18-40y) patients were enrolled. In addition, one of the 2 single high dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.

All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	AG019 Repeat High Dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

In this arm, AG019 was administered as a repeated high dose (8-week dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

<b>Arm title</b>	PHASE 1B - Single Low Dose - Adolescent
------------------	---

**Arm description:**

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat Low Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Arm type	Experimental
Investigational medicinal product name	AG019 Single Low Dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

In this arm, AG019 was administered as a single low dose (one-day dosing; one capsule in the morning and one capsule in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

<b>Arm title</b>	PHASE 1B - Single High Dose - Adolescent
------------------	--

**Arm description:**

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat High Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Arm type	Experimental
Investigational medicinal product name	AG019 Single High Dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

In this arm, AG019 was administered as a single high dose (one-day dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

<b>Arm title</b>	PHASE 1B - Repeat Low Dose - Adolescent
------------------	---

**Arm description:**

In this arm, 4 newly identified repeat low dose adolescent (12-17y) patients were enrolled. None of the 2 single low dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 4.

All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Arm type	Experimental
Investigational medicinal product name	AG019 Repeat Low Dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

In this arm, AG019 was administered as a repeated low dose (8-week dosing; one capsule in the morning and one capsule in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

<b>Arm title</b>	PHASE 1B - Repeat High Dose - Adolescent
------------------	--

**Arm description:**

In this arm, 4 newly identified repeat high dose adolescent (12-17y) patients were enrolled. In addition, one of the 2 single high dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.

All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Arm type	Experimental
Investigational medicinal product name	AG019 Repeat High Dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

In this arm, AG019 was administered as a repeated high dose (8-week dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

<b>Arm title</b>	PHASE 2A - Active AG019/teplizumab - Adults
------------------	---

**Arm description:**

A total of 10 adult (18-40y) patients was enrolled into this arm.

The first 2 patients in the overall Adult AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab.

Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment). After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor before allowing enrollment of the second staggered patient.

After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients (randomization ratio 4:1; 8 active and 2 placebo).

Arm type	Experimental
----------	--------------

Investigational medicinal product name	AG019 Repeat High Dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

In this arm, AG019 was administered as a repeated high dose (8-week dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

Investigational medicinal product name	Teplizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for dispersion for infusion
Routes of administration	Infusion , Intravenous use

**Dosage and administration details:**

Teplizumab was administered as a 12-day infusion cycle, during the first 12 days of AG019 treatment. Infusion volumes were calculated, based upon the patient's body surface area (BSA) and using the Mosteller formula, according to the following regimen:

- Day 1: 106 µg/m<sup>2</sup>
- Day 2: 425 µg/m<sup>2</sup>
- Day 3-12: 850 µg/m<sup>2</sup>

<b>Arm title</b>	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults
------------------	--

**Arm description:**

As part of the double-blind portion of the overall Adult AG019/teplizumab combination cohort, 2 patients were randomized to receive AG019-placebo and teplizumab-placebo.

Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 treatment).

All patients were followed up for a total of 12 months (8 weeks of treatment plus 10 months of post treatment follow-up).

Arm type	Placebo
Investigational medicinal product name	AG019-Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

**Dosage and administration details:**

In this arm, AG019-placebo was administered for 8 weeks at a daily dose of 3 capsules in the morning and 3 capsules in the evening. Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

Investigational medicinal product name	Teplizumab-placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for dispersion for infusion
Routes of administration	Infusion , Intravenous use

**Dosage and administration details:**

Teplizumab-placebo was administered as a 12-day infusion cycle, during the first 12 days of AG019-placebo treatment. Infusion volumes were calculated, based upon the patient's body surface area (BSA) and using the Mosteller formula, according to the following regimen:

- Day 1: 106 µg/m<sup>2</sup>
- Day 2: 425 µg/m<sup>2</sup>
- Day 3-12: 850 µg/m<sup>2</sup>

Note: teplizumab-placebo did not contain active ingredient, but as the double-blind placebo vials were formulated in an identical way as the active treatment, identical calculations were used to determine the



<b>Arm title</b>	PHASE 2A - Active AG019/teplizumab - Adolescents
------------------	--

## Arm description:

5 adolescent (12-17y) patients were enrolled into this arm.

The first 2 patients in the overall Adolescent AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab. Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment). After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor.

After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients. Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment after enrolment of 5 active patients and 1 placebo patient

Arm type	Experimental
Investigational medicinal product name	AG019 Repeat High Dose
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

## Dosage and administration details:

In this arm, AG019 was administered as a repeated high dose (8-week dosing; 3 capsules in the morning and 3 capsules in the evening). Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

Investigational medicinal product name	Teplizumab
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for dispersion for infusion
Routes of administration	Infusion , Intravenous use

## Dosage and administration details:

Teplizumab was administered as a 12-day infusion cycle, during the first 12 days of AG019 treatment. Infusion volumes were calculated, based upon the patient's body surface area (BSA) and using the Mosteller formula, according to the following regimen:

- Day 1: 106 µg/m<sup>2</sup>
- Day 2: 425 µg/m<sup>2</sup>
- Day 3-12: 850 µg/m<sup>2</sup>

<b>Arm title</b>	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
------------------	---

## Arm description:

As part of the double-blind portion of the overall Adolescent AG019/teplizumab combination cohort, 1 patient was randomized to receive AG019-placebo and teplizumab-placebo.

Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 - placebo treatment).

Follow-up was planned till 12 months (8 weeks of treatment plus 10 months of post treatment follow-up), however, the patient was lost to follow-up after the 9 months follow-up visit.

Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment in the overall Adolescent AG019/teplizumab combination cohort after enrollment of a total of 5 active patients and 1 placebo patient.

Arm type	Placebo
----------	---------

Investigational medicinal product name	AG019-Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Gastro-resistant capsule, hard
Routes of administration	Oral use

Dosage and administration details:

In this arm, AG019-placebo was administered for 8 weeks at a daily dose of 3 capsules in the morning and 3 capsules in the evening. Capsules were to be taken approximately 30-60 minutes before breakfast and dinner, respectively. Capsules were taken with an adequate volume of water, and were not to be damaged, opened or chewed.

Investigational medicinal product name	Teplizumab-placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Concentrate for dispersion for infusion
Routes of administration	Infusion , Intravenous use

Dosage and administration details:

Teplizumab-placebo was administered as a 12-day infusion cycle, during the first 12 days of AG019-placebo treatment. Infusion volumes were calculated, based upon the patient's body surface area (BSA) and using the Mosteller formula, according to the following regimen:

- Day 1: 106 µg/m<sup>2</sup>
- Day 2: 425 µg/m<sup>2</sup>
- Day 3-12: 850 µg/m<sup>2</sup>

Note: teplizumab-placebo did not contain active ingredient, but as the double-blind placebo vials were formulated in an identical way as the active treatment, identical calculations were used to determine the appropriate infusion volumes.

Number of subjects in period 1	PHASE 1B - Single Low Dose - Adult	PHASE 1B - Single High Dose - Adult	PHASE 1B - Repeat Low Dose - Adult
Started	2	2	5
Completed	2	2	5
Not completed	0	0	0
Consent withdrawn by subject	-	-	-
Adverse event, non-fatal	-	-	-
Lost to follow-up	-	-	-

Number of subjects in period 1	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Single Low Dose - Adolescent	PHASE 1B - Single High Dose - Adolescent
Started	5	2	2
Completed	4	2	2
Not completed	1	0	0
Consent withdrawn by subject	1	-	-
Adverse event, non-fatal	-	-	-
Lost to follow-up	-	-	-

Number of subjects in period 1	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent	PHASE 2A - Active AG019/teplizumab - Adults
Started	4	5	10
Completed	4	4	10
Not completed	0	1	0

Consent withdrawn by subject	-	1	-
Adverse event, non-fatal	-	-	-
Lost to follow-up	-	-	-

Number of subjects in period 1	PHASE 2A - AG019- placebo/teplizumab- placebo - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019- placebo/teplizumab- placebo - Adolescents
Started	2	5	1
Completed	2	4	0
Not completed	0	1	1
Consent withdrawn by subject	-	-	-
Adverse event, non-fatal	-	1	-
Lost to follow-up	-	-	1

## Baseline characteristics

### Reporting groups

Reporting group title	PHASE 1B - Single Low Dose - Adult
-----------------------	------------------------------------

#### Reporting group description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat Low Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Reporting group title	PHASE 1B - Single High Dose - Adult
-----------------------	-------------------------------------

#### Reporting group description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability.

After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat High Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Reporting group title	PHASE 1B - Repeat Low Dose - Adult
-----------------------	------------------------------------

#### Reporting group description:

In this arm, 4 newly identified repeat low dose adult (18-42y) patients were enrolled. In addition, one of the 2 single low dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.

All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Reporting group title	PHASE 1B - Repeat High Dose - Adult
-----------------------	-------------------------------------

#### Reporting group description:

In this arm, 4 newly identified repeat high dose adult (18-40y) patients were enrolled. In addition, one of the 2 single high dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.

All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Reporting group title	PHASE 1B - Single Low Dose - Adolescent
-----------------------	---

#### Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat Low Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Reporting group title	PHASE 1B - Single High Dose - Adolescent
-----------------------	--

Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat High Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Reporting group title	PHASE 1B - Repeat Low Dose - Adolescent
-----------------------	---

Reporting group description:

In this arm, 4 newly identified repeat low dose adolescent (12-17y) patients were enrolled. None of the 2 single low dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 4.

All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Reporting group title	PHASE 1B - Repeat High Dose - Adolescent
-----------------------	--

Reporting group description:

In this arm, 4 newly identified repeat high dose adolescent (12-17y) patients were enrolled. In addition, one of the 2 single high dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.

All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Reporting group title	PHASE 2A - Active AG019/teplizumab - Adults
-----------------------	---

Reporting group description:

A total of 10 adult (18-40y) patients was enrolled into this arm.

The first 2 patients in the overall Adult AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab.

Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment).

After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor before allowing enrollment of the second staggered patient.

After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients (randomization ratio 4:1; 8 active and 2 placebo).

Reporting group title	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults
-----------------------	--

Reporting group description:

As part of the double-blind portion of the overall Adult AG019/teplizumab combination cohort, 2 patients were randomized to receive AG019-placebo and teplizumab-placebo.

Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 treatment).

All patients were followed up for a total of 12 months (8 weeks of treatment plus 10 months of post treatment follow-up).

Reporting group title	PHASE 2A - Active AG019/teplizumab - Adolescents
-----------------------	--

Reporting group description:

5 adolescent (12-17y) patients were enrolled into this arm.

The first 2 patients in the overall Adolescent AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab. Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment). After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor. After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients. Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment after enrolment of 5 active patients and 1 placebo patient

Reporting group title	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
-----------------------	---

Reporting group description:

As part of the double-blind portion of the overall Adolescent AG019/teplizumab combination cohort, 1 patient was randomized to receive AG019-placebo and teplizumab-placebo.

Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 - placebo treatment).

Follow-up was planned till 12 months (8 weeks of treatment plus 10 months of post treatment follow-up), however, the patient was lost to follow-up after the 9 months follow-up visit.

Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment in the overall Adolescent AG019/teplizumab combination cohort after enrollment of a total of 5 active patients and 1 placebo patient.

Reporting group values	PHASE 1B - Single Low Dose - Adult	PHASE 1B - Single High Dose - Adult	PHASE 1B - Repeat Low Dose - Adult
Number of subjects	2	2	5
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	0	0
Adults (18-64 years)	2	2	5
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
median	38.0	19.5	26.0
standard deviation	± 5.7	± 2.1	± 8.9
Gender categorical			
Units: Subjects			
Female	0	1	1
Male	2	1	4
Ethnicity			
Units: Subjects			
Hispanic or latino	0	1	0
Not hispanic or latino	2	1	5
baseline serological cytomegalovirus positivity			
Units: Subjects			
Negative	2	2	5
Positive	0	0	0

Missing	0	0	0
baseline serological Epstein-Barr virus positivity Units: Subjects			
Negative	2	2	2
Positive	0	0	3
Autoantibody positivity - GAD65 Units: Subjects			
Negative	0	0	0
Positive	1	2	5
Missing	1	0	0
Autoantibody positivity - IA-2 Units: Subjects			
Negative	1	1	2
Positive	0	1	2
Missing	1	0	1
Autoantibody positivity - ZnT8 Units: Subjects			
Negative	0	1	0
Positive	1	1	2
Missing	1	0	3
Autoantibody positivity - Insulin Units: Subjects			
Negative	1	1	2
Positive	0	1	3
Missing	1	0	0
Inulin required at baseline Units: Subjects			
Yes	1	2	5
No	1	0	0
Baseline HbA1c Units: percent			
arithmetic mean	0	0	6.38
standard deviation	± 0	± 0	± 0.56
time from diagnosis to treatment Units: days			
arithmetic mean	84.5	45.5	91.0
standard deviation	± 44.5	± 20.5	± 38.2
Baseline IDAA1c Units: none			
arithmetic mean	0.00	0.00	7.385
standard deviation	± 0.00	± 0.00	± 1.303
Fasting C-peptide Units: nmol/L			
arithmetic mean	0.00	0.00	0.27
standard deviation	± 0.00	± 0.00	± 0.15
Peak stimulated C-peptide Units: nmol/L			
arithmetic mean	0	0	0.92
standard deviation	± 0	± 0	± 0.35
2H C-peptide AUC Units: nmol/L			

arithmetic mean	0.000	0.000	0.62
standard deviation	± 0.000	± 0.000	± 0.28
Total daily insulin use			
Units: IU/kg/d			
arithmetic mean	0.000	0.00	0.23
standard deviation	± 0.00	± 0.00	± 0.18

<b>Reporting group values</b>	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Single Low Dose - Adolescent	PHASE 1B - Single High Dose - Adolescent
Number of subjects	5	2	2
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	2	2
Adults (18-64 years)	5	0	0
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous			
Units: years			
median	22.0	16.5	17.0
standard deviation	± 7.4	± 0.7	± 0.0
Gender categorical			
Units: Subjects			
Female	2	2	0
Male	3	0	2
Ethnicity			
Units: Subjects			
Hispanic or latino	1	0	1
Not hispanic or latino	4	2	1
baseline serological cytomegalovirus positivity			
Units: Subjects			
Negative	5	2	2
Positive	0	0	0
Missing	0	0	0
baseline serological Epstein-Barr virus positivity			
Units: Subjects			
Negative	4	2	2
Positive	1	0	0
Autoantibody positivity - GAD65			
Units: Subjects			
Negative	0	0	0
Positive	5	1	1
Missing	0	1	1
Autoantibody positivity - IA-2			



Units: Subjects			
Negative	1	0	0
Positive	4	1	0
Missing	0	1	2
Autoantibody positivity - ZnT8			
Units: Subjects			
Negative	2	0	0
Positive	2	0	0
Missing	1	2	2
Autoantibody positivity - Insulin			
Units: Subjects			
Negative	2	0	1
Positive	3	0	0
Missing	0	2	1
Inulin required at baseline			
Units: Subjects			
Yes	4	2	2
No	1	0	0
Baseline HbA1c			
Units: percent			
arithmetic mean	7.00	0	0
standard deviation	± 1.57	± 0	± 0
time from diagnosis to treatment			
Units: days			
arithmetic mean	100.0	146.0	113.0
standard deviation	± 42.2	± 4.2	± 53.7
Baseline IDAA1c			
Units: none			
arithmetic mean	8.248	0.00	0.00
standard deviation	± 2.369	± 0.00	± 0.00
Fasting C-peptide			
Units: nmol/L			
arithmetic mean	0.38	0.00	0.00
standard deviation	± 0.20	± 0.00	± 0.00
Peak stimulated C-peptide			
Units: nmol/L			
arithmetic mean	1.26	0	0
standard deviation	± 1.00	± 0	± 0
2H C-peptide AUC			
Units: nmol/L			
arithmetic mean	0.89	0.000	0.000
standard deviation	± 0.61	± 0.000	± 0.000
Total daily insulin use			
Units: IU/kg/d			
arithmetic mean	0.31	0.00	0.00
standard deviation	± 0.24	± 0.00	± 0.00
<b>Reporting group values</b>	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent	PHASE 2A - Active AG019/teplizumab - Adults
Number of subjects	4	5	10

Age categorical Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	4	5	0
Adults (18-64 years)	0	0	10
From 65-84 years	0	0	0
85 years and over	0	0	0
Age continuous Units: years			
median	14.0	14.0	26.5
standard deviation	± 2.2	± 1.9	± 6.7
Gender categorical Units: Subjects			
Female	2	3	4
Male	2	2	6
Ethnicity Units: Subjects			
Hispanic or latino	0	0	0
Not hispanic or latino	4	5	10
baseline serological cytomegalovirus positivity Units: Subjects			
Negative	3	5	5
Positive	1	0	5
Missing	0	0	0
baseline serological Epstein-Barr virus positivity Units: Subjects			
Negative	4	4	4
Positive	0	1	6
Autoantibody positivity - GAD65 Units: Subjects			
Negative	1	0	0
Positive	3	5	10
Missing	0	0	0
Autoantibody positivity - IA-2 Units: Subjects			
Negative	2	2	5
Positive	2	2	3
Missing	0	1	2
Autoantibody positivity - ZnT8 Units: Subjects			
Negative	1	1	2
Positive	3	3	5
Missing	0	1	3
Autoantibody positivity - Insulin			

Units: Subjects			
Negative	1	2	5
Positive	1	2	0
Missing	2	1	5
Inulin required at baseline			
Units: Subjects			
Yes	4	5	10
No	0	0	0
Baseline HbA1c			
Units: percent			
arithmetic mean	6.40	6.28	6.92
standard deviation	± 0.51	± 0.89	± 1.42
time from diagnosis to treatment			
Units: days			
arithmetic mean	95.0	126.4	101.0
standard deviation	± 21.3	± 19.4	± 35.9
Baseline IDAA1c			
Units: none			
arithmetic mean	9.090	8.392	8.412
standard deviation	± 1.093	± 2.470	± 1.725
Fasting C-peptide			
Units: nmol/L			
arithmetic mean	0.33	0.27	0.18
standard deviation	± 0.08	± 0.14	± 0.13
Peak stimulated C-peptide			
Units: nmol/L			
arithmetic mean	0.97	0.81	0.71
standard deviation	± 0.45	± 0.21	± 0.26
2H C-peptide AUC			
Units: nmol/L			
arithmetic mean	0.78	0.57	0.48
standard deviation	± 0.35	± 0.13	± 0.19
Total daily insulin use			
Units: IU/kg/d			
arithmetic mean	0.67	0.53	0.37
standard deviation	± 0.27	± 0.46	± 0.14

Reporting group values	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
Number of subjects	2	5	1
Age categorical			
Units: Subjects			
In utero	0	0	0
Preterm newborn infants (gestational age < 37 wks)	0	0	0
Newborns (0-27 days)	0	0	0
Infants and toddlers (28 days-23 months)	0	0	0
Children (2-11 years)	0	0	0
Adolescents (12-17 years)	0	5	1
Adults (18-64 years)	2	0	0

From 65-84 years	0	0	0
85 years and over	0	0	0

Age continuous Units: years median standard deviation	29.0 ± 5.7	14.0 ± 1.1	12.0 ± 0.0
Gender categorical Units: Subjects			
Female	1	3	1
Male	1	2	0
Ethnicity Units: Subjects			
Hispanic or latino	0	0	0
Not hispanic or latino	2	5	1
baseline serological cytomegalovirus positivity Units: Subjects			
Negative	1	4	1
Positive	1	0	0
Missing	0	1	0
baseline serological Epstein-Barr virus positivity Units: Subjects			
Negative	0	4	1
Positive	2	1	0
Autoantibody positivity - GAD65 Units: Subjects			
Negative	0	2	0
Positive	2	3	1
Missing	0	0	0
Autoantibody positivity - IA-2 Units: Subjects			
Negative	1	1	0
Positive	1	4	1
Missing	0	0	0
Autoantibody positivity - ZnT8 Units: Subjects			
Negative	0	0	0
Positive	0	3	0
Missing	2	2	1
Autoantibody positivity - Insulin Units: Subjects			
Negative	1	3	0
Positive	1	1	1
Missing	0	1	0
Inulin required at baseline Units: Subjects			
Yes	2	5	1
No	0	0	0

Baseline HbA1c Units: percent arithmetic mean standard deviation	7.35 ± 3.04	7.14 ± 2.43	8.40 ± 0.00
time from diagnosis to treatment Units: days arithmetic mean standard deviation	70.0 ± 15.6	122.6 ± 36.3	90.0 ± 0.00
Baseline IDAA1c Units: none arithmetic mean standard deviation	8.530 ± 4.540	9.605 ± 2.583	10.640 ± 0.00
Fasting C-peptide Units: nmol/L arithmetic mean standard deviation	0.36 ± 0.22	0.25 ± 0.06	0.16 ± 0.00
Peak stimulated C-peptide Units: nmol/L arithmetic mean standard deviation	1.10 ± 0.11	0.76 ± 0.29	0.28 ± 0.00
2H C-peptide AUC Units: nmol/L arithmetic mean standard deviation	0.73 ± 0.01	0.57 ± 0.21	0.25 ± 0.00
Total daily insulin use Units: IU/kg/d arithmetic mean standard deviation	0.30 ± 0.37	0.51 ± 0.18	0.56 ± 0.00

<b>Reporting group values</b>	Total		
Number of subjects	45		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	19		
Adults (18-64 years)	26		
From 65-84 years	0		
85 years and over	0		
Age continuous Units: years median standard deviation	-		
Gender categorical Units: Subjects			
Female	20		
Male	25		

Ethnicity			
Units: Subjects			
Hispanic or latino	3		
Not hispanic or latino	42		
baseline serological cytomegalovirus positivity			
Units: Subjects			
Negative	37		
Positive	7		
Missing	1		
baseline serological Epstein-Barr virus positivity			
Units: Subjects			
Negative	31		
Positive	14		
Autoantibody positivity - GAD65			
Units: Subjects			
Negative	3		
Positive	39		
Missing	3		
Autoantibody positivity - IA-2			
Units: Subjects			
Negative	16		
Positive	21		
Missing	8		
Autoantibody positivity - ZnT8			
Units: Subjects			
Negative	7		
Positive	20		
Missing	18		
Autoantibody positivity - Insulin			
Units: Subjects			
Negative	19		
Positive	13		
Missing	13		
Inulin required at baseline			
Units: Subjects			
Yes	43		
No	2		
Baseline HbA1c			
Units: percent			
arithmetic mean			
standard deviation	-		
time from diagnosis to treatment			
Units: days			
arithmetic mean			
standard deviation	-		
Baseline IDAA1c			
Units: none			
arithmetic mean			
standard deviation	-		
Fasting C-peptide			

Units: nmol/L arithmetic mean standard deviation	-		
Peak stimulated C-peptide Units: nmol/L arithmetic mean standard deviation	-		
2H C-peptide AUC Units: nmol/L arithmetic mean standard deviation	-		
Total daily insulin use Units: IU/kg/d arithmetic mean standard deviation	-		

## End points

### End points reporting groups

Reporting group title	PHASE 1B - Single Low Dose - Adult
Reporting group description: 2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient. After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat Low Dose cohort to begin. Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.	
Reporting group title	PHASE 1B - Single High Dose - Adult
Reporting group description: 2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient. After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat High Dose cohort to begin. Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.	
Reporting group title	PHASE 1B - Repeat Low Dose - Adult
Reporting group description: In this arm, 4 newly identified repeat low dose adult (18-42y) patients were enrolled. In addition, one of the 2 single low dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5. All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months). The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s). After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.	
Reporting group title	PHASE 1B - Repeat High Dose - Adult
Reporting group description: In this arm, 4 newly identified repeat high dose adult (18-40y) patients were enrolled. In addition, one of the 2 single high dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5. All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months). The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s). After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.	
Reporting group title	PHASE 1B - Single Low Dose - Adolescent
Reporting group description: 2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient. After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat Low Dose cohort to begin. Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.	



Reporting group title	PHASE 1B - Single High Dose - Adolescent
-----------------------	--

Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat High Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Reporting group title	PHASE 1B - Repeat Low Dose - Adolescent
-----------------------	---

Reporting group description:

In this arm, 4 newly identified repeat low dose adolescent (12-17y) patients were enrolled. None of the 2 single low dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 4.

All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Reporting group title	PHASE 1B - Repeat High Dose - Adolescent
-----------------------	--

Reporting group description:

In this arm, 4 newly identified repeat high dose adolescent (12-17y) patients were enrolled. In addition, one of the 2 single high dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.

All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Reporting group title	PHASE 2A - Active AG019/teplizumab - Adults
-----------------------	---

Reporting group description:

A total of 10 adult (18-40y) patients was enrolled into this arm.

The first 2 patients in the overall Adult AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab.

Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment).

After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor before allowing enrollment of the second staggered patient.

After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients (randomization ratio 4:1; 8 active and 2 placebo).

Reporting group title	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults
-----------------------	--

Reporting group description:

As part of the double-blind portion of the overall Adult AG019/teplizumab combination cohort, 2 patients were randomized to receive AG019-placebo and teplizumab-placebo.

Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 treatment).

All patients were followed up for a total of 12 months (8 weeks of treatment plus 10 months of post treatment follow-up).

Reporting group title	PHASE 2A - Active AG019/teplizumab - Adolescents
-----------------------	--

Reporting group description:

5 adolescent (12-17y) patients were enrolled into this arm.

The first 2 patients in the overall Adolescent AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab. Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment). After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor. After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients. Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment after enrolment of 5 active patients and 1 placebo patient

Reporting group title	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
-----------------------	---

Reporting group description:

As part of the double-blind portion of the overall Adolescent AG019/teplizumab combination cohort, 1 patient was randomized to receive AG019-placebo and teplizumab-placebo.

Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 - placebo treatment).

Follow-up was planned till 12 months (8 weeks of treatment plus 10 months of post treatment follow-up), however, the patient was lost to follow-up after the 9 months follow-up visit.

Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment in the overall Adolescent AG019/teplizumab combination cohort after enrollment of a total of 5 active patients and 1 placebo patient.

Subject analysis set title	Safety Analysis Set
----------------------------	---------------------

Subject analysis set type	Safety analysis
---------------------------	-----------------

Subject analysis set description:

The safety population will include all patients who received at least one dose of AG019. Only patients with clear documentation that no study medication was received may be excluded from analysis.

Patients were analyzed according to dose received. This population is used for all data summaries.

Subject analysis set title	PD-ITT
----------------------------	--------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

The Pharmacodynamic Intention To Treat (PD-ITT) Analysis Set. All patients in the repeat dose and combination cohorts who received at least one dose of AG019 were included in the PD-ITT analysis set.

Subject analysis set title	PD-PP
----------------------------	-------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

The Pharmacodynamic Per Protocol (PD-PP) Analysis Set. All data from patients in the repeat dose and combination cohorts who received at least 75% of the scheduled doses of AG019 and at least one dose of teplizumab in the combination cohorts and had no major protocol deviations affecting the main PD endpoints at the time point of data collection were included in the PD-PP analysis set.

Refer to the SAP for details on compliance calculation and designation of major PDs affecting the main PD endpoints.

Subject analysis set title	PK-ITT
----------------------------	--------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

The Pharmacokinetic Intention To Treat (PK-ITT) Analysis Set. All patients in the repeat dose and combination cohorts who received at least one dose of AG019 were included in the PK-ITT analysis set.

Subject analysis set title	PK-PP
----------------------------	-------

Subject analysis set type	Sub-group analysis
---------------------------	--------------------

Subject analysis set description:

The Pharmacokinetic Per Protocol (PK-PP) Analysis Set. All data from patients in the repeat dose and combination cohorts who received at least 75% of the scheduled doses of AG019 and at least one dose of teplizumab in the combination cohorts and had no major protocol deviations affecting the main PK endpoints at the time point of data collection are included in the PK-PP analysis set.

## Primary: incidence of treatment emergent adverse events up to 6 months

End point title	incidence of treatment emergent adverse events up to 6 months <sup>[1]</sup>
-----------------	--

End point description:

The incidence of TEAE reported up to the 6-month follow-up visit. The TEAE are counted once within each patient on the preferred term level.

End point type	Primary
----------------	---------

End point timeframe:

up to 6 months follow-up

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: FIH study, descriptive statistics only.

End point values	PHASE 1B - Single Low Dose - Adult	PHASE 1B - Single High Dose - Adult	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	2	5	5
Units: number of TEAE	1	1	6	19

End point values	PHASE 1B - Single Low Dose - Adolescent	PHASE 1B - Single High Dose - Adolescent	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	2	4	5
Units: number of TEAE	1	1	28	19

End point values	PHASE 2A - Active AG019/teplizu mab - Adults	PHASE 2A - AG019-placebo/teplizu mab-placebo - Adults	PHASE 2A - Active AG019/teplizu mab - Adolescents	PHASE 2A - AG019-placebo/teplizu mab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	5	1
Units: number of TEAE	91	25	22	1

End point values	Safety Analysis Set			
Subject group type	Subject analysis set			
Number of subjects analysed	45			
Units: number of TEAE	215			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Presence of AG019 L. lactis bacteria in whole blood

End point title	Presence of AG019 L. lactis bacteria in whole blood <sup>[2]</sup>
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Blood sample at screening, during treatment (Day 12 and Day 56) and post treatment (Day 90; 34 days after last treatment)

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	4	5
Units: Yes/No	0	0	0	0

End point values	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	4	1
Units: Yes/No	0	0	0	0

End point values	PK-ITT			
Subject group type	Subject analysis set			
Number of subjects analysed	36			
Units: Yes/No	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Indication for exposure of AG019 secreted hPINS protein in plasma

End point title	Indication for exposure of AG019 secreted hPINS protein in plasma <sup>[3]</sup>
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Plasma sample at screening, during treatment (Day 12 and Day 56) and post treatment (Day 90; 34 days after last treatment)

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	4	5
Units: Yes/No	0	0	0	0

End point values	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	4	1
Units: Yes/No	0	0	0	0

End point values	PK-ITT			
Subject group type	Subject analysis set			
Number of subjects analysed	36			
Units: Yes/No	0			

## Statistical analyses

No statistical analyses for this end point

## Secondary: Indication for exposure of AG019 secreted hIL-10 protein in plasma

End point title	Indication for exposure of AG019 secreted hIL-10 protein in plasma <sup>[4]</sup>
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Plasma sample at screening, during treatment (Day 12 and Day 56) and post treatment (Day 90; 34 days after last treatment)

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	4	5
Units: Yes/No	0	0	0	0

End point values	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	4	1
Units: Yes/No	0	0	0	0

End point values	PK-ITT			
Subject group type	Subject analysis set			
Number of subjects analysed	36			
Units: Yes/No	0			

## Statistical analyses

No statistical analyses for this end point

### Secondary: Presence of AG019 L.lactis bacteria in fecal excretion

End point title	Presence of AG019 L.lactis bacteria in fecal excretion <sup>[5]</sup>
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

Fecal sample at screening, on the last day of treatment (at Day 56) and every 2 days thereafter (Day 58, 60, 62 and 64) for a total of 5 sampling points

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat High Dose - Adolescent	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	4 <sup>[6]</sup>	10	2
Units: Yes/No	3	3	9	0

Notes:

[6] - 1 subject was unwilling to provide samples

End point values	PHASE 2A - Active AG019/teplizu mab - Adolescents	PHASE 2A - AG019-placebo/teplizu mab-placebo - Adolescents	PK-ITT	
Subject group type	Reporting group	Reporting group	Subject analysis set	
Number of subjects analysed	3 <sup>[7]</sup>	1	25	
Units: Yes/No	3	0	18	

Notes:

[7] - 1 subject stopped after one dose of AG019

1 subject was unable to provide samples

## Statistical analyses

No statistical analyses for this end point

## Secondary: hypoglycemic events - before treatment

End point title	hypoglycemic events - before treatment <sup>[8]</sup>
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

before treatment

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	4	5
Units: number of events				
level 2	5	1	2	3
level 3	0	0	0	0
unknown	0	0	0	0

End point values	PHASE 2A - Active AG019/teplizu mab - Adults	PHASE 2A - AG019-placebo/teplizu mab-placebo - Adults	PHASE 2A - Active AG019/teplizu mab - Adolescents	PHASE 2A - AG019-placebo/teplizu mab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	5	1
Units: number of events				
level 2	30	1	0	0
level 3	1	0	0	0

unknown	5	0	0	0
---------	---	---	---	---

## Statistical analyses

No statistical analyses for this end point

## Secondary: hypoglycemic events - during treatment

End point title | hypoglycemic events - during treatment<sup>[9]</sup>

End point description:

End point type | Secondary

End point timeframe:  
during treatment

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.  
Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	4	5
Units: number of events				
level 2	10	4	3	7
level 3	0	0	1	0
unknown	0	2	1	2

End point values	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	5	1
Units: number of events				
level 2	51	3	2	1
level 3	2	0	1	0
unknown	12	2	0	0

## Statistical analyses

No statistical analyses for this end point



**Secondary: hypoglycemic events - after treatment**

End point title	hypoglycemic events - after treatment <sup>[10]</sup>
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

after treatment up to 12 months

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	4	5
Units: number of events				
level 2	51	0	3	126
level 3	0	0	0	1
unknown	0	0	6	15

End point values	PHASE 2A - Active AG019/teplizu mab - Adults	PHASE 2A - AG019-placebo/teplizu mab-placebo - Adults	PHASE 2A - Active AG019/teplizu mab - Adolescents	PHASE 2A - AG019-placebo/teplizu mab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	5	1
Units: number of events				
level 2	46	11	3	0
level 3	1	0	0	0
unknown	46	1	0	0

**Statistical analyses**

No statistical analyses for this end point

**Secondary: Incidence of treatment emergent adverse events according to severity**

End point title	Incidence of treatment emergent adverse events according to severity
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

entire study (through 12 months follow-up)

<b>End point values</b>	PHASE 1B - Single Low Dose - Adult	PHASE 1B - Single High Dose - Adult	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	2	5	5
Units: number of events				
Grade 1	1	1	8	24
Grade 2	0	0	2	7
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

<b>End point values</b>	PHASE 1B - Single Low Dose - Adolescent	PHASE 1B - Single High Dose - Adolescent	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	2	4	5
Units: number of events				
Grade 1	1	1	27	27
Grade 2	0	0	9	3
Grade 3	0	0	0	0
Grade 4	0	0	0	0
Grade 5	0	0	0	0

<b>End point values</b>	PHASE 2A - Active AG019/teplizu mab - Adults	PHASE 2A - AG019- placebo/teplizu mab-placebo - Adults	PHASE 2A - Active AG019/teplizu mab - Adolescents	PHASE 2A - AG019- placebo/teplizu mab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	5	1
Units: number of events				
Grade 1	84	27	16	2
Grade 2	35	10	9	0
Grade 3	7	0	1	0
Grade 4	1	0	0	0
Grade 5	0	0	0	0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Incidence of treatment emergent adverse events according to relatedness

End point title	Incidence of treatment emergent adverse events according to relatedness
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

entire study (through 12 months follow-up)

End point values	PHASE 1B - Single Low Dose - Adult	PHASE 1B - Single High Dose - Adult	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	2	5	5
Units: number of events				
reasonably related	1	1	0	4
not reasonably related	0	0	10	27

End point values	PHASE 1B - Single Low Dose - Adolescent	PHASE 1B - Single High Dose - Adolescent	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	2	4	5
Units: number of events				
reasonably related	0	1	4	3
not reasonably related	1	0	32	27

End point values	PHASE 2A - Active AG019/teplizu mab - Adults	PHASE 2A - AG019- placebo/teplizu mab-placebo - Adults	PHASE 2A - Active AG019/teplizu mab - Adolescents	PHASE 2A - AG019- placebo/teplizu mab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	5	1
Units: number of events				
reasonably related	41	22	1	0
not reasonably related	86	15	25	2

## Statistical analyses

No statistical analyses for this end point

## Secondary: Total daily insulin use

End point title	Total daily insulin use <sup>[11]</sup>
-----------------	---

End point description:

note: as no standard deviation was calculated, the values are entered as zero to avoid validation conflicts.

End point type	Secondary
----------------	-----------

End point timeframe:

at regular time points (represented by the different categories) throughout the study.

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	4	4	4
Units: IU/kg/day				
arithmetic mean (standard deviation)				
Day 1	0.3 (± 0)	0.23 (± 0)	0.7 (± 0)	0.27 (± 0)
Day 12	0.24 (± 0)	0.2 (± 0)	0.56 (± 0)	0.21 (± 0)
Day 56	0.29 (± 0)	0.23 (± 0)	0.65 (± 0)	0.26 (± 0)
Day 90	0.35 (± 0)	0.26 (± 0)	0.61 (± 0)	0.35 (± 0)
Day 180	0.36 (± 0)	0.28 (± 0)	0.58 (± 0)	0.50 (± 0)
Day 360	0.46 (± 0)	0.34 (± 0)	0.65 (± 0)	0.39 (± 0)

End point values	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	4	1
Units: IU/kg/day				
arithmetic mean (standard deviation)				
Day 1	0.36 (± 0)	0.29 (± 0)	0.5 (± 0)	0.48 (± 0)
Day 12	0.4 (± 0)	0.32 (± 0)	0.57 (± 0)	0.3 (± 0)
Day 56	0.4 (± 0)	0.36 (± 0)	0.37 (± 0)	0.53 (± 0)
Day 90	0.36 (± 0)	0.42 (± 0)	0.46 (± 0)	0.6 (± 0)
Day 180	0.39 (± 0)	0.28 (± 0)	0.47 (± 0)	0.55 (± 0)
Day 360	0.35 (± 0)	0.34 (± 0)	0.54 (± 0)	0 (± 0)

## Statistical analyses

No statistical analyses for this end point

## Secondary: preproinsulin specific CD8+ T cells

End point title	preproinsulin specific CD8+ T cells <sup>[12]</sup>
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

3 months (Day 90) and 6 months (Day 180) as represented in the categories

Notes:

[12] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat High Dose - Adolescent	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	4 <sup>[13]</sup>	9 <sup>[14]</sup>	2
Units: log-fold change from baseline arithmetic mean (standard deviation)				
Day 90	-0.137 (± 0.126)	-0.084 (± 0.012)	-0.044 (± 0.125)	0.007 (± 0.095)
Day 180	-0.047 (± 0.034)	-0.121 (± 0.159)	-0.064 (± 0.098)	-0.148 (± 0.181)

Notes:

[13] - Day 180: n=2 (2 data points missing)

[14] - Day 180: n=7 (2 data points missing)

End point values	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	4	1		
Units: log-fold change from baseline arithmetic mean (standard deviation)				
Day 90	-0.095 (± 0.142)	0.140 (± 0.000)		
Day 180	-0.179 (± 0.162)	0.052 (± 0.000)		

## Statistical analyses

No statistical analyses for this end point

## Secondary: Incidence of treatment emergent adverse events up to 12 months

End point title	Incidence of treatment emergent adverse events up to 12 months
-----------------	--

End point description:

Incidence of all reported TEAE up to the 12-month follow-up visit. The TEAE are counted once within each patient on the preferred term level.

End point type	Secondary
End point timeframe: entire study, up to 12 months	

End point values	PHASE 1B - Single Low Dose - Adult	PHASE 1B - Single High Dose - Adult	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	2	5	5
Units: number of events	1	1	8	26

End point values	PHASE 1B - Single Low Dose - Adolescent	PHASE 1B - Single High Dose - Adolescent	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	2	2	4	5
Units: number of events	1	1	33	26

End point values	PHASE 2A - Active AG019/teplizu mab - Adults	PHASE 2A - AG019- placebo/teplizu mab-placebo - Adults	PHASE 2A - Active AG019/teplizu mab - Adolescents	PHASE 2A - AG019- placebo/teplizu mab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10	2	5	1
Units: number of events	97	26	23	2

## Statistical analyses

No statistical analyses for this end point

## Secondary: HbA1c values over time

End point title	HbA1c values over time <sup>[15]</sup>
End point description:	

End point type	Secondary
End point timeframe: every 3 months up to 12 months	

Notes:

[15] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	4 <sup>[16]</sup>	4 <sup>[17]</sup>	4 <sup>[18]</sup>
Units: percent				
arithmetic mean (standard deviation)				
Day 90	5.84 (± 0.43)	5.65 (± 0.57)	6.33 (± 0.67)	6.48 (± 1.16)
Day 180	5.88 (± 0.18)	5.58 (± 0.41)	7.17 (± 1.68)	5.90 (± 0.71)
Day 270	5.80 (± 0.39)	5.83 (± 0.61)	8.65 (± 2.05)	6.70 (± 1.54)
Day 360	5.96 (± 0.42)	6.05 (± 0.31)	7.08 (± 1.91)	7.53 (± 1.66)

Notes:

[16] - Day 270: n=3

[17] - Day 180: n=3

Day 270: n=2

[18] - Day 180: n=2

Day 270 and Day 360: n=3

End point values	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9 <sup>[19]</sup>	2 <sup>[20]</sup>	4 <sup>[21]</sup>	1 <sup>[22]</sup>
Units: percent				
arithmetic mean (standard deviation)				
Day 90	5.86 (± 0.94)	6.35 (± 1.48)	6.40 (± 0.75)	7.30 (± 0.00)
Day 180	6.00 (± 1.06)	7.20 (± 2.97)	6.35 (± 0.73)	6.50 (± 0.00)
Day 270	6.36 (± 0.87)	9.60 (± 0.00)	6.27 (± 0.65)	6.00 (± 0.00)
Day 360	6.42 (± 0.98)	9.60 (± 0.00)	6.58 (± 0.63)	0.00 (± 0.00)

Notes:

[19] - Day 180 and Day 270: n=8

[20] - Day 270 and Day 360: n=1

[21] - Day 90 and Day 270: n=3

[22] - Day 360: n=0 (sample not obtained)

End point values	PD-PP			
Subject group type	Subject analysis set			
Number of subjects analysed	33 <sup>[23]</sup>			
Units: percent				
arithmetic mean (standard deviation)				
Day 90	6.09 (± 0.84)			
Day 180	6.18 (± 1.08)			
Day 270	6.51 (± 1.26)			
Day 360	6.62 (± 1.21)			

Notes:

[23] - Day 90: n=32

Day 180: n=29

Day 270: n=26

Day 360: n=30

## Statistical analyses

**Secondary: IDAA1c values over time**End point title IDAA1c values over time<sup>[24]</sup>

End point description:

End point type Secondary

End point timeframe:

every 3 months up to 12 months

Notes:

[24] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	4 <sup>[25]</sup>	4 <sup>[26]</sup>	4 <sup>[27]</sup>
Units: percent				
arithmetic mean (standard deviation)				
Day 90	7.24 (± 1.02)	6.67 (± 0.78)	8.76 (± 0.93)	7.87 (± 1.48)
Day 180	7.34 (± 0.84)	6.71 (± 0.89)	9.70 (± 2.54)	7.96 (± 1.81)
Day 270	7.38 (± 1.05)	6.93 (± 0.76)	12.73 (± 1.60)	8.58 (± 2.08)
Day 360	7.78 (± 1.20)	7.40 (± 0.74)	9.66 (± 2.49)	9.08 (± 1.22)

Notes:

[25] - Day 270: n=3

[26] - Day 180: n=3

Day 270: n=2

[27] - Day 180: n=2

Day 270 and Day 360: n=3

End point values	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	9 <sup>[28]</sup>	2 <sup>[29]</sup>	4 <sup>[30]</sup>	1 <sup>[31]</sup>
Units: percent				
arithmetic mean (standard deviation)				
Day 90	7.23 (± 0.82)	8.03 (± 3.24)	8.51 (± 0.04)	9.70 (± 0.00)
Day 180	7.61 (± 0.79)	8.30 (± 4.24)	8.23 (± 1.28)	8.70 (± 0.00)
Day 270	7.81 (± 0.72)	11.40 (± 0.00)	8.76 (± 0.42)	7.44 (± 0.00)
Day 360	7.83 (± 0.79)	12.80 (± 0.00)	8.72 (± 0.97)	0.00 (± 0.00)

Notes:

[28] - Day 180 and Day 270: n=8

[29] - Day 270 and Day 360: n=1

[30] - Day 90 and Day 270: n=2

[31] - Day 360: n=0

End point values	PD-PP			
------------------	-------	--	--	--



Subject group type	Subject analysis set			
Number of subjects analysed	31 <sup>[32]</sup>			
Units: percent				
arithmetic mean (standard deviation)				
Day 90	7.65 (± 1.27)			
Day 180	7.85 (± 1.55)			
Day 270	8.31 (± 1.86)			
Day 360	8.42 (± 1.59)			

Notes:

[32] - Day 180: n=29

Day 270: n=25

Day 360: n=30

## Statistical analyses

No statistical analyses for this end point

## Secondary: Mean 2H C-peptide AUC over time

End point title	Mean 2H C-peptide AUC over time <sup>[33]</sup>
-----------------	---

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

2H AUC at baseline and at 3, 6 and 12 months as depicted in the categories. Calculated on PD-PP population.

Notes:

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	5	4	4 <sup>[34]</sup>
Units: nmol/L				
arithmetic mean (standard deviation)				
Baseline	0.619 (± 0.276)	0.925 (± 0.705)	0.784 (± 0.350)	0.631 (± 0.015)
Day 90	0.514 (± 0.240)	0.719 (± 0.508)	0.689 (± 0.395)	0.573 (± 0.226)
Day 180	0.592 (± 0.324)	0.729 (± 0.576)	0.517 (± 0.199)	0.432 (± 0.330)
Day 360	0.418 (± 0.257)	0.500 (± 0.327)	0.428 (± 0.134)	0.512 (± 0.484)

Notes:

[34] - Day 180: n=3

Day 360: n=2

End point values	PHASE 2A - Active AG019/teplizu mab - Adults	PHASE 2A - AG019-placebo/teplizu mab-placebo - Adults	PHASE 2A - Active AG019/teplizu mab - Adolescents	PHASE 2A - AG019-placebo/teplizu mab-placebo - Adolescents
------------------	--	---	---	--

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10 <sup>[35]</sup>	2 <sup>[36]</sup>	4 <sup>[37]</sup>	1 <sup>[38]</sup>
Units: nmol/L				
arithmetic mean (standard deviation)				
Baseline	0.483 (± 0.194)	0.726 (± 0.010)	0.630 (± 0.183)	0.247 (± 0.000)
Day 90	0.544 (± 0.222)	0.681 (± 0.188)	0.573 (± 0.144)	0.253 (± 0.000)
Day 180	0.517 (± 0.230)	0.532 (± 0.088)	0.766 (± 0.148)	0.191 (± 0.000)
Day 360	0.464 (± 0.255)	0.396 (± 0.000)	0.665 (± 0.160)	0.000 (± 0.000)

Notes:

[35] - Day 360: n=9

[36] - Day 360: n=1

[37] - Day 90: n=3

[38] - Day 360: n=0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percent change from baseline values of mean 2H C-peptide AUC

End point title	Percent change from baseline values of mean 2H C-peptide AUC <sup>[39]</sup>
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

3, 6 and 12 months as represented by the categories

Notes:

[39] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	4	4	4 <sup>[40]</sup>
Units: percent				
arithmetic mean (standard deviation)				
Day 90	81.516 (± 11.023)	78.719 (± 18.248)	82.995 (± 16.692)	90.385 (± 34.049)
Day 180	91.978 (± 29.620)	76.631 (± 17.043)	72.067 (± 23.968)	67.655 (± 50.038)
Day 360	61.671 (± 22.054)	57.570 (± 32.472)	58.812 (± 13.311)	79.293 (± 73.862)

Notes:

[40] - Day 180: n=3

Day 360: n=2

End point values	PHASE 2A - Active	PHASE 2A - AG019-	PHASE 2A - Active	PHASE 2A - AG019-
------------------	-------------------	-------------------	-------------------	-------------------

	AG019/teplizu mab - Adults	placebo/teplizu mab-placebo - Adults	AG019/teplizu mab - Adolescents	placebo/teplizu mab-placebo - Adolescents
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10 <sup>[41]</sup>	2 <sup>[42]</sup>	4 <sup>[43]</sup>	1 <sup>[44]</sup>
Units: percent				
arithmetic mean (standard deviation)				
Day 90	120.507 (± 45.663)	93.681 (± 24.610)	106.876 (± 29.070)	102.408 (± 0.000)
Day 180	111.581 (± 35.749)	73.250 (± 11.021)	123.805 (± 10.341)	77.313 (± 0.000)
Day 360	100.239 (± 35.792)	53.997 (± 0.000)	107.863 (± 23.169)	0.000 (± 0.000)

Notes:

[41] - Day 360: n=9

[42] - Day 360: n=1

[43] - Day 90: n=3

[44] - Day 360: n=0

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage C-peptide responders

End point title	Percentage C-peptide responders <sup>[45]</sup>
-----------------	---

End point description:

A patient was designated as responder when his or her C-peptide change from baseline was either non-negative or, if negative, represented a coefficient of variance (CV) less than or equal to 9.7% (Greenbaum et al., 2012)

End point type	Secondary
----------------	-----------

End point timeframe:

percent of patients designated as C-peptide responders at 6 and 12 months

Notes:

[45] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: not all treatment groups were subject to this endpoint analysis

End point values	PHASE 1B - Repeat Low Dose - Adult	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Repeat Low Dose - Adolescent	PHASE 1B - Repeat High Dose - Adolescent
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	4	4	3 <sup>[46]</sup>
Units: percentage				
Day 180	60	50	25	33
Day 360	20	25	0	50

Notes:

[46] - Day 360: n=2

End point values	PHASE 2A - Active AG019/teplizu mab - Adults	PHASE 2A - AG019- placebo/teplizu mab-placebo - Adults	PHASE 2A - Active AG019/teplizu mab - Adolescents	PHASE 2A - AG019- placebo/teplizu mab-placebo - Adolescents
------------------	---	--	---	---

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	10 <sup>[47]</sup>	2 <sup>[48]</sup>	4	1 <sup>[49]</sup>
Units: percentage				
Day 180	70	0	100	0
Day 360	67	0	100	0

Notes:

[47] - Day 360: n=9

[48] - Day 360: n=1

[49] - Day 360: n=0

## Statistical analyses

No statistical analyses for this end point

## Adverse events

---

### Adverse events information

---

Timeframe for reporting adverse events:

Adverse events are collected from signature of informed consent until completion of the study (or premature withdrawal).

Adverse event reporting additional description:

All adverse events are listed, regardless of treatment emergence, severity, or relationship to AG019 or teplizumab. The results of the primary endpoint (incidence of TEAE up to 6 months) are outlined in the Endpoints section.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	21.0

### Reporting groups

Reporting group title	PHASE 1B - Single Low Dose - Adult
-----------------------	------------------------------------

Reporting group description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat Low Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Reporting group title	PHASE 1B - Single High Dose - Adult
-----------------------	-------------------------------------

Reporting group description:

2 adults (18-40y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability.

After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adult Repeat High Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Reporting group title	PHASE 1B - Repeat Low Dose - Adult
-----------------------	------------------------------------

Reporting group description:

In this arm, 4 newly identified repeat low dose adult (18-42y) patients were enrolled. In addition, one of the 2 single low dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.

All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Reporting group title	PHASE 1B - Repeat High Dose - Adult
-----------------------	-------------------------------------

Reporting group description:

In this arm, 4 newly identified repeat high dose adult (18-40y) patients were enrolled. In addition, one of the 2 single high dose adult patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.

All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was

reviewed by the DSMB, prior to opening the next cohort for enrollment.

Reporting group title	PHASE 1B - Single Low Dose - Adolescent
-----------------------	---

Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the low dose of AG019 (1 capsule in the morning and one capsule in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat Low Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Reporting group title	PHASE 1B - Repeat Low Dose - Adolescent
-----------------------	---

Reporting group description:

In this arm, 4 newly identified repeat low dose adolescent (12-17y) patients were enrolled. None of the 2 single low dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 4.

All patients were treated with a repeated low dose of AG019 (1 capsule in the morning and 1 capsule in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Reporting group title	PHASE 1B - Single High Dose - Adolescent
-----------------------	--

Reporting group description:

2 adolescents (12-17y) were enrolled in a staggered way and were treated for one day with the high dose of AG019 (3 capsules in the morning and 3 capsules in the evening). Patients were treated for one day and followed up for an additional 3 days, to monitor for safety and tolerability. After completion of the first single dose patient, the medical monitor reviewed the data prior to allowing enrollment of the second single dose patient.

After completion of the second single dose patient, the medical monitor reviewed all available data prior to allowing enrollment in the Adolescent Repeat High Dose cohort to begin.

Single dose patients were offered the option of being re-enrolled as repeat dose patients in the same dose and age cohort.

Reporting group title	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults
-----------------------	--

Reporting group description:

As part of the double-blind portion of the overall Adult AG019/teplizumab combination cohort, 2 patients were randomized to receive AG019-placebo and teplizumab-placebo.

Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 treatment).

All patients were followed up for a total of 12 months (8 weeks of treatment plus 10 months of post treatment follow-up).

Reporting group title	PHASE 1B - Repeat High Dose - Adolescent
-----------------------	--

Reporting group description:

In this arm, 4 newly identified repeat high dose adolescent (12-17y) patients were enrolled. In addition, one of the 2 single high dose adolescent patients was re-enrolled in this repeat dose cohort, totalling the number of patients in this cohort to 5.

All patients were treated with a repeated high dose of AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks), and followed up for another 10 months after treatment completion (total duration of participation: 12 months).

The first 2 patients were enrolled in a staggered way. Data review after the 7-day follow-up visit (one week after treatment start) was conducted before enrolling the next patient(s).

After the 7-day follow-up visit of the last enrolled patient, all available data from all cohorts was reviewed by the DSMB, prior to opening the next cohort for enrollment.

Reporting group title	PHASE 2A - Active AG019/teplizumab - Adults
-----------------------	---

Reporting group description:

A total of 10 adult (18-40y) patients was enrolled into this arm.

The first 2 patients in the overall Adult AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab.

Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment).

After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion

cycle), the data was reviewed by the medical monitor before allowing enrollment of the second staggered patient.

After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients (randomization ratio 4:1; 8 active and 2 placebo).

Reporting group title	PHASE 2A - Active AG019/teplizumab - Adolescents
-----------------------	--

Reporting group description:

10 adolescent (12-17y) patients was enrolled into this arm.

The first 2 patients in the overall Adolescent AG019/teplizumab combination cohort were enrolled in a staggered way, and were treated in an open-label fashion with active AG019 and active teplizumab.

Patients were treated with active AG019 (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and active teplizumab (12 daily IV infusions during the first 12 days of AG019 treatment).

After the Day 12 follow-up visit of the first staggered patient (completion of the teplizumab infusion cycle), the data was reviewed by the medical monitor.

After the Day 12 follow-up visit of the second staggered patient (completion of the teplizumab infusion cycle), all data from all cohorts was reviewed by the DSMB before allowing enrollment of the remaining double-blind patients. Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment after enrolment of 6 active patients and 1 placebo patient

Reporting group title	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
-----------------------	---

Reporting group description:

As part of the double-blind portion of the overall Adolescent AG019/teplizumab combination cohort, 2 patients were randomized to receive AG019-placebo and teplizumab-placebo.

Patients were treated with AG019-placebo (3 capsules in the morning and 3 capsules in the evening, daily for 8 weeks) and teplizumab-placebo (12 daily IV infusions during the first 12 days of AG019 treatment).

All patients were followed up for a total of 12 months (8 weeks of treatment plus 10 months of post treatment follow-up).

Note: due to the COVID-19 pandemic, the Sponsor decided to terminate recruitment in the overall Adolescent AG019/teplizumab combination cohort after enrollment of a total of 6 active patients and 1 placebo patient.

Serious adverse events	PHASE 1B - Single Low Dose - Adult	PHASE 1B - Single High Dose - Adult	PHASE 1B - Repeat Low Dose - Adult
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Single Low Dose - Adolescent	PHASE 1B - Repeat Low Dose - Adolescent
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Serious adverse events	PHASE 1B - Single High Dose - Adolescent	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults	PHASE 1B - Repeat High Dose - Adolescent
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)

number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

<b>Serious adverse events</b>	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019-placebo/teplizumab-placebo - Adolescents
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Frequency threshold for reporting non-serious adverse events: 0 %

<b>Non-serious adverse events</b>	PHASE 1B - Single Low Dose - Adult	PHASE 1B - Single High Dose - Adult	PHASE 1B - Repeat Low Dose - Adult
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 2 (50.00%)	2 / 2 (100.00%)	5 / 5 (100.00%)
Vascular disorders			
Pallor			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Administration site pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Catheter site pruritus			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Catheter site related reaction			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Chest pain			



subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Infusion site irritation			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Immune system disorders			
Cytokine release syndrome			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Seasonal allergy			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Selective IgA immunodeficiency			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			

Dysmenorrhoea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Scrotal irritation			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal discomfort			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nasal discomfort			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Painful respiration			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tonsillar hypertrophy			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			

Anxiety			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Attention deficit hyperactivity disorder			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Panic attack			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Suicidal ideation			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood glucose decreased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood potassium increased			

subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Body temperature decreased			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
C-reactive protein increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Eosinophil count increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Epstein-Barr virus test positive			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Glycosylated haemoglobin increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Liver function test abnormal			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Monocyte count decreased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Platelet count increased subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Protein total increased subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Prothrombin time prolonged subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Red blood cell count decreased subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Foot fracture subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Hand fracture subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Joint injury subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	1 / 2 (50.00%) 1	0 / 5 (0.00%) 0
Ligament sprain			

subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tooth fracture			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dizziness postural			

subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Presyncope			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tension headache			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Eosinophilia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Erythropenia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Lymphadenopathy			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Microcytic anaemia subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Ear and labyrinth disorders			
Motion sickness subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	1 / 5 (20.00%) 1
Vertigo subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Eye disorders			
Retinopathy subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Abdominal tenderness subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Chronic gastritis subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Coeliac disease			



subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Dyspepsia			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	1	0	0
Flatulence			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Glossitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tongue dry			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Vomiting			

subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Pruritus			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Growing pains			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Medial tibial stress syndrome			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Muscle twitching			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Systemic lupus erythematosus			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Body tinea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			

subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Gastroenteritis viral			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Infectious mononucleosis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Medical device site infection			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	2 / 5 (40.00%)
occurrences (all)	0	0	3
Otitis externa			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			

subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	3 / 5 (60.00%) 4
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Viral infection subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Metabolism and nutrition disorders			
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	1 / 2 (50.00%) 3	0 / 5 (0.00%) 0
Iron deficiency subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0

<b>Non-serious adverse events</b>	PHASE 1B - Repeat High Dose - Adult	PHASE 1B - Single Low Dose - Adolescent	PHASE 1B - Repeat Low Dose - Adolescent
Total subjects affected by non-serious adverse events subjects affected / exposed	5 / 5 (100.00%)	1 / 2 (50.00%)	4 / 4 (100.00%)
Vascular disorders			
Pallor subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
General disorders and administration site conditions			
Administration site pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0

Catheter site pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Catheter site pruritus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Catheter site related reaction			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Influenza like illness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Infusion site irritation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Immune system disorders			
Cytokine release syndrome			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Selective IgA immunodeficiency subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	1 / 4 (25.00%) 1
Reproductive system and breast disorders			
Dysmenorrhoea subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	1 / 4 (25.00%) 1
Scrotal irritation subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Vulvovaginal discomfort subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			
Cough subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Dyspnoea exertional subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Nasal congestion subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Nasal discomfort subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Oropharyngeal pain subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	1 / 4 (25.00%) 1
Painful respiration			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Productive cough subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Tonsillar hypertrophy subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 2 (0.00%) 0	1 / 4 (25.00%) 1
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Attention deficit hyperactivity disorder subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Depression subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Panic attack subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	1 / 4 (25.00%) 1
Suicidal ideation subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Investigations			
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	1 / 4 (25.00%) 1
Blood bilirubin increased			



subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood glucose decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood potassium increased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Blood urea increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Body temperature decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eosinophil count increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Epstein-Barr virus test positive			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Glycosylated haemoglobin increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
International normalised ratio increased			

subjects affected / exposed	2 / 5 (40.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	4	0	0
Liver function test abnormal			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Monocyte count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	1	0	1
Platelet count increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Protein total increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Red blood cell count decreased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Weight increased			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	2	0	1
Injury, poisoning and procedural complications			
Contusion			

subjects affected / exposed	2 / 5 (40.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)
occurrences (all)	3	1	0
Foot fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hand fracture			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Joint injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Ligament sprain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Limb injury			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Thermal burn			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Tooth fracture			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Wound			
subjects affected / exposed	0 / 5 (0.00%)	1 / 2 (50.00%)	0 / 4 (0.00%)
occurrences (all)	0	1	0
Skin laceration			
subjects affected / exposed	2 / 5 (40.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	2	0	1
Cardiac disorders			

Palpitations subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Dizziness postural subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Paraesthesia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	1 / 4 (25.00%) 1
Presyncope subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	2 / 4 (50.00%) 2
Tension headache subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Eosinophilia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Erythropenia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	1 / 4 (25.00%) 1
Iron deficiency anaemia			

subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Leukopenia subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 2 (0.00%) 0	2 / 4 (50.00%) 3
Lymphadenopathy subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	2 / 4 (50.00%) 2
Lymphopenia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Microcytic anaemia subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	1 / 5 (20.00%) 1	0 / 2 (0.00%) 0	1 / 4 (25.00%) 3
Ear and labyrinth disorders Motion sickness subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	1 / 4 (25.00%) 1
Tinnitus subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Eye disorders Retinopathy subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Gastrointestinal disorders Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 5 (0.00%) 0	0 / 2 (0.00%) 0	0 / 4 (0.00%) 0
Abdominal pain			

subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Abdominal tenderness			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Chronic gastritis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Coeliac disease			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	2 / 5 (40.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	4	0	1
Dyspepsia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Glossitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nausea			

subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	2 / 4 (50.00%)
occurrences (all)	0	0	2
Stomatitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tongue dry			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Dermatitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Dermatitis contact			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Dry skin			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Pruritus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Rash			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Rash papular			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Growing pains			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Medial tibial stress syndrome			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Muscle twitching			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Neck pain			



subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	2
Systemic lupus erythematosus			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Body tinea			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Infectious mononucleosis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Influenza			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Medical device site infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	2	0	0
Otitis externa			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0

Pharyngitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1
Skin infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Upper respiratory tract infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	2 / 4 (50.00%)
occurrences (all)	2	0	2
Urinary tract infection			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	1	0	0
Viral infection			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	2
Hypoglycaemia			
subjects affected / exposed	1 / 5 (20.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	8	0	0
Iron deficiency			
subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	0 / 4 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			

subjects affected / exposed	0 / 5 (0.00%)	0 / 2 (0.00%)	1 / 4 (25.00%)
occurrences (all)	0	0	1

<b>Non-serious adverse events</b>	PHASE 1B - Single High Dose - Adolescent	PHASE 2A - AG019-placebo/teplizumab-placebo - Adults	PHASE 1B - Repeat High Dose - Adolescent
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 2 (100.00%)	2 / 2 (100.00%)	4 / 5 (80.00%)
Vascular disorders			
Pallor			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Administration site pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Catheter site pain			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Catheter site pruritus			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Catheter site related reaction			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Chest pain			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Chills			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	3	0
Influenza like illness			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Infusion site irritation			

subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Immune system disorders			
Cytokine release syndrome			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Seasonal allergy			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Selective IgA immunodeficiency			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Scrotal irritation			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal discomfort			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	2	0
Dyspnoea exertional			

subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Nasal congestion			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Nasal discomfort			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Oropharyngeal pain			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Painful respiration			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Productive cough			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tonsillar hypertrophy			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Attention deficit hyperactivity disorder			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Panic attack			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Suicidal ideation			

subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood glucose decreased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood potassium increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Body temperature decreased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			

subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Eosinophil count increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Epstein-Barr virus test positive			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Glycosylated haemoglobin increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
International normalised ratio increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Liver function test abnormal			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Monocyte count decreased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Platelet count increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Protein total increased			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Prothrombin time prolonged			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1

Red blood cell count decreased subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	1 / 5 (20.00%) 1
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Foot fracture subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	1 / 5 (20.00%) 1
Hand fracture subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	1 / 5 (20.00%) 1
Joint injury subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Ligament sprain subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Limb injury subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Muscle strain subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	1 / 5 (20.00%) 1
Procedural pain subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Thermal burn			



subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Tooth fracture subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Wound subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Skin laceration subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Sinus bradycardia subjects affected / exposed occurrences (all)	1 / 2 (50.00%) 1	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Nervous system disorders Dizziness subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Dizziness postural subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	1 / 2 (50.00%) 1	0 / 5 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	2 / 2 (100.00%) 11	1 / 5 (20.00%) 2
Paraesthesia subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Presyncope subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Tension headache			

subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Eosinophilia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Erythropenia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 2 (0.00%)	2 / 2 (100.00%)	0 / 5 (0.00%)
occurrences (all)	0	2	0
Leukopenia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	2 / 5 (40.00%)
occurrences (all)	0	0	2
Lymphadenopathy			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Microcytic anaemia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Motion sickness			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tinnitus			

subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Vertigo			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Eye disorders			
Retinopathy			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Abdominal pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Abdominal tenderness			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Chronic gastritis			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Coeliac disease			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Dyspepsia			

subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Gingival bleeding			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Glossitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	1	0	1
Stomatitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tongue dry			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	2 / 5 (40.00%)
occurrences (all)	0	0	3
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0

Dermatitis contact			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Eczema			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Rash papular			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Back pain			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Growing pains			

subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	2
Medial tibial stress syndrome			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Muscle twitching			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Systemic lupus erythematosus			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Infections and infestations			
Body tinea			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Hordeolum			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1

Infectious mononucleosis			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Influenza			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Medical device site infection			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	0 / 5 (0.00%)
occurrences (all)	0	1	0
Otitis externa			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Pharyngitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Sinusitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1
Tonsillitis			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	0 / 5 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	2 / 5 (40.00%)
occurrences (all)	0	0	4
Urinary tract infection			
subjects affected / exposed	0 / 2 (0.00%)	0 / 2 (0.00%)	1 / 5 (20.00%)
occurrences (all)	0	0	1

Viral infection subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Metabolism and nutrition disorders			
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Hypoglycaemia subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0
Iron deficiency subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	1 / 2 (50.00%) 1	0 / 5 (0.00%) 0
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 2 (0.00%) 0	0 / 2 (0.00%) 0	0 / 5 (0.00%) 0

<b>Non-serious adverse events</b>	PHASE 2A - Active AG019/teplizumab - Adults	PHASE 2A - Active AG019/teplizumab - Adolescents	PHASE 2A - AG019- placebo/teplizumab- placebo - Adolescents
Total subjects affected by non-serious adverse events subjects affected / exposed	10 / 10 (100.00%)	5 / 5 (100.00%)	1 / 1 (100.00%)
Vascular disorders			
Pallor subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
General disorders and administration site conditions			
Administration site pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 5 (20.00%) 1	0 / 1 (0.00%) 0
Catheter site pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Catheter site pruritus subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Catheter site related reaction			



subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Fatigue			
subjects affected / exposed	2 / 10 (20.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	2	1	0
Influenza like illness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Infusion site irritation			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	2
Pyrexia			
subjects affected / exposed	2 / 10 (20.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	2	2	0
Immune system disorders			
Cytokine release syndrome			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Seasonal allergy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Selective IgA immunodeficiency			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Reproductive system and breast disorders			
Dysmenorrhoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Scrotal irritation			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Vulvovaginal discomfort			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	1	1	0
Dyspnoea exertional			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 10 (0.00%)	2 / 5 (40.00%)	0 / 1 (0.00%)
occurrences (all)	0	2	0
Nasal discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	6	0	0
Painful respiration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Tonsillar hypertrophy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			

Anxiety			
subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	1 / 1 (100.00%)
occurrences (all)	1	1	1
Attention deficit hyperactivity disorder			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	1 / 1 (100.00%)
occurrences (all)	0	1	1
Depression			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Panic attack			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Suicidal ideation			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	1	1	0
Blood glucose decreased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Blood potassium increased			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood urea increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Blood uric acid increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Body temperature decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
C-reactive protein increased			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Eosinophil count increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Epstein-Barr virus test positive			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Glycosylated haemoglobin increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Liver function test abnormal			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Lymphocyte count decreased			
subjects affected / exposed	2 / 10 (20.00%)	2 / 5 (40.00%)	0 / 1 (0.00%)
occurrences (all)	3	2	0
Monocyte count decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0

Neutrophil count decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Platelet count increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Protein total increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Prothrombin time prolonged subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Red blood cell count decreased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Weight increased subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 5 (20.00%) 1	0 / 1 (0.00%) 0
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Foot fracture subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Hand fracture subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Joint injury subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Ligament sprain			

subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Limb injury			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Muscle strain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Thermal burn			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tooth fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Wound			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Skin laceration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Palpitations			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Sinus bradycardia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Dizziness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dizziness postural			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	5 / 10 (50.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	7	3	0
Paraesthesia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Presyncope			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tension headache			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Eosinophilia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Erythropenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Leukopenia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	3	0	0
Lymphadenopathy			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Lymphopenia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	6	0	0

Microcytic anaemia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Neutropenia subjects affected / exposed occurrences (all)	3 / 10 (30.00%) 5	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Ear and labyrinth disorders			
Motion sickness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Vertigo subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Eye disorders			
Retinopathy subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Gastrointestinal disorders			
Abdominal discomfort subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Abdominal pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 5 (20.00%) 1	0 / 1 (0.00%) 0
Abdominal pain upper subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Abdominal tenderness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Chronic gastritis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Coeliac disease			



subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Constipation			
subjects affected / exposed	1 / 10 (10.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	2	1	0
Diarrhoea			
subjects affected / exposed	4 / 10 (40.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	4	0	0
Dyspepsia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Glossitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Lip dry			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Nausea			
subjects affected / exposed	4 / 10 (40.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	4	1	0
Stomatitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Tongue dry			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Toothache			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Vomiting			

subjects affected / exposed	4 / 10 (40.00%)	2 / 5 (40.00%)	0 / 1 (0.00%)
occurrences (all)	12	2	0
Skin and subcutaneous tissue disorders			
Acne			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Dermatitis contact			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Rash			
subjects affected / exposed	5 / 10 (50.00%)	1 / 5 (20.00%)	0 / 1 (0.00%)
occurrences (all)	5	1	0
Rash maculo-papular			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Rash papular			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Scab			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Back pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Growing pains			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Medial tibial stress syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Muscle twitching			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	2 / 10 (20.00%)	2 / 5 (40.00%)	0 / 1 (0.00%)
occurrences (all)	5	2	0
Neck pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Pain in extremity			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Systemic lupus erythematosus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Body tinea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hordeolum			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Infectious mononucleosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Influenza			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Medical device site infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Nasopharyngitis			
subjects affected / exposed	3 / 10 (30.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	3	0	0
Otitis externa			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Pharyngitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Sinusitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tonsillitis			
subjects affected / exposed	2 / 10 (20.00%)	0 / 5 (0.00%)	0 / 1 (0.00%)
occurrences (all)	2	0	0
Tooth abscess			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Urinary tract infection subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Viral infection subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Metabolism and nutrition disorders			
Hyperglycaemia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Hypoglycaemia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Iron deficiency subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0
Vitamin D deficiency subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 5 (0.00%) 0	0 / 1 (0.00%) 0

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
05 April 2018	minor changes
16 April 2018	Staggered enrolment of single dose patients Changes to I/E criteria requested internally and by central IRB Clarification in description of assessments Addition of HCV and HIV in infectious disease monitoring Addition of insulin dose adjusted HbA1c Addition of CGM Addition of tuberculosis test
08 October 2018	Addition of upper age limit (40 years) Clarification on the dose to be used in Phase 2a Clarifications to I/E criteria Addition of summary of non-clinical studies Clarifications to assessments Changes to grading and reporting of hypoglycemic and hyperglycemic events.
11 April 2019	Extension of screening period to 4 weeks Addition of HBV to infectious disease monitoring Change of Safety Management and pharmacovigilance vendor Clarifications to assessments Addition of Interim Analysis protocol section Clarification to infusion withholding criteria
19 September 2019	Change to inclusion criteria and infusion withholding criteria (bilirubin) Clarification on replacement of patients who cannot receive the first dose of teplizumab due to withholding criteria
03 February 2020	Clarification of assessments Modification of infusion withholding criteria and criteria for suspension of enrollment
11 June 2020	Addition of SARS-Cov2 PCR test Addition of interim analyses

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
------	--------------	--------------

30 August 2019	In line with the protocol defined enrollment suspension criteria for teplizumab infusion withholding in >20% of exposed patients, enrollment was temporarily paused, pending data review by the DSMB. Data review was performed on 04-Sep-2019 and the DSMB subsequently confirmed that enrollment could resume.	04 September 2019
11 October 2019	In line with the protocol defined enrollment suspension criteria for teplizumab infusion withholding in >20% of exposed patients, enrollment was temporarily paused, pending data review by the DSMB. Data review was performed on 16-Oct-2019 and the DSMB subsequently confirmed that enrollment could resume.	16 October 2019
18 March 2020	After consulting with the DSMB, the Sponsor decided to temporarily suspend enrollment of new patients into the study due to the COVID-19 pandemic. In the following mnths, the Sponsor has generated a set of measures to protect the safety and well being of all study patients, and to ensure the integrity of the data. These included, amongst others, generation of a protocol amendment, generation of a checklist for reopening sites on a case-by-case basis, taking measures to allow for remote data monitoring, taking measures to enable home healthcare visits for study patients, and reinforcing the DSMB with 2 infectious disease experts. On 24-Jun-2020 all measures were presented to the DSMB, who concluded that enrollment could resume on a site-by-site basis, provided that all required measures were in place.	24 June 2020

Notes:

## Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

As this was a first in human study, it was exclusively designed to demonstrate the safety and tolerability of AG019 (alone and in association with teplizumab). It was not powered to demonstrate efficacy (sample size too low).

Notes: